Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
Study CX-659-401 is a multicenter, open-label, phase 2 study of mivavotinib to evaluate the
single-agent activity of mivavotinib in patients with relapsed/refractory non-GCB/ABC DLBCL,
incorporating ctDNA-based next-generation sequencing (NGS) to identify DLBCL patients
harboring MyD88 and/or CD79B mutations within the study. This goal of this strategy is to
evaluate its activity both in the cell-of-origin subgroup of non-GCB/ABC DLBCL and in the
genetically defined subgroups of MyD88/CD79B-mutated and wild type DLBCL.